What type of study is this?

This is a Human Clinical Trial study (also classified as: In Vitro Study, Pre-Registered Trial).

December 8, 2025BloodOpen Access

A phase 1/2 study of GB3226, a novel dual inhibitor of ENL-yeats and FLT3, in patients with relapsed/refractory Acute Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

Tumor regression observed in models after administering GB3226, a dual inhibitor of ENL-YEATS and FLT3.
Phase 1 trial identifies safety and tolerability for GB3226, emphasizing pharmacokinetics over 28-day cycles.
Open-label trial assesses pharmacodynamics and biomarkers including CD11b and venetoclax response.
Clinical trial may offer new treatment avenues for acute myeloid leukemia, a condition with unmet medical need.

No takes yet. Share an insight, caveat, or question.

Phase 1/2 trial evaluates safety and tumor regression in relapsed acute myeloid leukemia, suggesting GB3226's potential with biomarkers.

Maiti et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark